Joerg Herrmann MDProfessor of Medicine, Mayo Graduate School of Medicine, Rochester, Minnesota
Dr. Joerg Herrmann received his medical training at Ruhr University, Bochum, Germany, and completed his internship in internal medicine at the University Clinic in Essen. Following a postdoctoral research fellowship, he pursued the clinician–investigator track in internal medicine-cardiology, and further training in interventional cardiology at the Mayo Clinic, Rochester, Minnesota. He then joined the staff of the Department of Cardiovascular Diseases at the Mayo Clinic, Rochester. Currently, he is a Professor of Medicine at the Mayo Graduate School of Medicine and serves as the director of the Cardio-Oncology Clinic and the research director of the Ischemic Heart Disease program.
Dr. Herrmann has been receiving NIH research funding, serves as a reviewer for over 30 journals, including all major cardiovascular journals. He currently is the chair of the Scientific Committee of the International Cardio-Oncology Society and an associated editor of several journals including the European Heart Journal (EHJ), EHJ Open, Trends in Cardiovascular Medicine, International Journal of Cardiology, Frontiers in Cardiovascular Medicine, and Current Cardiology Reports. He is also a regular contributor to Braunwald's Heart Disease, the associated editor of Trends in Cardiovascular Medicine, and the editor of the Cardio-Oncology Companion Book to Braunwald’s Heart Disease as well as the textbook Clinical Cardio-Oncology.
His main research interests are cardio-oncology, cardiac biomarkers, periprocedural myocardial infarction, atherosclerosis, and vascular biology.
Dr. Joerg Herrmann participated in the 2014 and 2016 Ponatinib in CML Cardio-Oncology Advisory Board meeting organized by ARIAD Pharmaceuticals, the 2016 Carfilzomib Advisory Board meeting organized by Amgen and is a member of the Institute for Cardio-Oncology advisory panel sponsored by Bristol-Myers Squib. He also reports disclosures from Pfizer.
Recent Contributions to PracticeUpdate:
- AI ECG as a Novel Screening Tool to Detect a Newly Abnormal LVEF After Anthracycline-Based Cancer Therapy
- 2023 Top Story in Cardiology: The STOP-CA Trial
- Atorvastatin for Anthracycline-Associated Cardiac Dysfunction
- Coronary Artery Restenosis Treatment With a Plain Balloon, Drug-Coated Balloon, or Drug-Eluting Stent: 10-Year Outcomes
- ACC 2023: Recommendations From Dr. Joerg Herrmann
- 2022 Top Story in Cardiology: Cardiovascular Toxicities and Immune Checkpoint Inhibitors
- The Genome-Wide Polygenic Score Informs CAD Risk in Childhood Cancer Survivors
- Statins and LVEF Following Doxorubicin Treatment
- ESC 2022: Recommendations From Dr. Joerg Herrmann
- Incidence of Cardiovascular Events in Patients Treated With Immune Checkpoint Inhibitors